EMAIL THIS PAGE TO A FRIEND

Immunotherapy

Ursolic acid attenuates lipopolysaccharide-induced acute lung injury in a mouse model.


PMID 23256797

Abstract

To assess whether ursolic acid (UA) can attenuate lipopolysachharide (LPS)-induced acute lung injury and improve the survival time in a mouse model. The mice were challenged with LPS and survival time was monitored from 0-96 h after LPS treatment. TNF-α, IL-6, IL-1β, HMGB1, nitric oxide (NO) and IL-10 concentration in serum were measured by ELISA. Myeloperoxidase activity, malondialdehyde, lung wet:dry weight ratio and lung permeability in lung tissues were detected. NF-κB, HMGB1 and inducible NO synthase in the lungs were detected by western blot. UA markedly rescued lethality, improved survival time and lung pathological changes, inhibited TNF-α, IL-6, IL-1β, HMGB1 and NO, and increased IL-10 expression. In addition, UA can also decrease myeloperoxidase, malondialdehyde, lung wet:dry weight ratio and lung permeability. UA attenuated NF-κB, HMGB1 and inducible NO synthase protein expression in the lungs. The results suggest that UA is capable of improving survival time and LPS-induced acute lung injury. UA has a potentially therapeutic role in septic shock.